Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jagsonpal Pharmaceuticals Ltd

₹ 209 -1.02%
21 May - close price
jagsonpal.com BSE: 507789 NSE: JAGSNPHARM
About

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]

Key Points

Business Overview:[1][2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands

Website BSE NSE
  • Market Cap ₹ 1,388 Cr.
  • Current Price ₹ 209
  • High / Low ₹ 328 / 109
  • Stock P/E 34.9
  • Book Value ₹ 36.1
  • Dividend Yield 0.96 %
  • ROCE 23.0 %
  • ROE 18.6 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 38.2% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 46.0%
  • Debtor days have improved from 23.1 to 17.9 days.
  • Company's working capital requirements have reduced from 35.2 days to 11.1 days

Cons

  • The company has delivered a poor sales growth of 11.1% over past five years.
  • Earnings include an other income of Rs.27.9 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
51.23 60.60 60.53 60.14 55.45 60.15 57.83 47.23 43.49 61.44 74.69 74.03 58.56
50.45 53.42 47.62 51.50 50.01 51.52 49.46 43.83 40.82 51.19 58.40 58.19 49.85
Operating Profit 0.78 7.18 12.91 8.64 5.44 8.63 8.37 3.40 2.67 10.25 16.29 15.84 8.71
OPM % 1.52% 11.85% 21.33% 14.37% 9.81% 14.35% 14.47% 7.20% 6.14% 16.68% 21.81% 21.40% 14.87%
0.37 -3.15 1.12 1.74 2.56 2.00 2.27 2.52 2.49 -1.85 1.65 25.51 2.56
Interest 0.06 0.01 0.03 0.18 0.20 0.15 0.22 0.23 0.22 0.22 0.23 0.26 0.26
Depreciation 0.65 0.19 0.20 0.33 0.48 0.39 0.46 0.41 0.40 1.07 2.34 2.41 2.31
Profit before tax 0.44 3.83 13.80 9.87 7.32 10.09 9.96 5.28 4.54 7.11 15.37 38.68 8.70
Tax % 31.82% 23.50% 24.49% 21.07% 23.50% 25.87% 25.00% 24.81% 21.59% 25.04% 25.44% 17.27% 24.48%
0.31 2.92 10.41 7.79 5.60 7.48 7.47 3.96 3.55 5.33 11.46 31.99 6.58
EPS in Rs 0.05 0.45 1.59 1.19 0.85 1.14 1.14 0.60 0.54 0.81 1.73 4.82 0.99
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
144 138 143 144 127 167 159 188 218 237 209 269
133 129 132 138 138 157 150 169 192 203 186 218
Operating Profit 11 9 12 6 -11 9 9 19 26 34 23 51
OPM % 7% 6% 8% 4% -9% 6% 5% 10% 12% 14% 11% 19%
0 0 1 13 0 1 3 4 3 2 9 28
Interest 5 4 5 3 1 1 1 1 0 0 1 1
Depreciation 3 3 3 2 0 1 1 1 2 1 2 8
Profit before tax 3 2 4 14 -12 9 9 22 27 35 30 70
Tax % 16% 30% 20% 18% -1% 20% 16% 22% 29% 23% 25% 21%
2 1 3 12 -12 7 8 17 19 27 22 55
EPS in Rs 0.32 0.18 0.50 1.81 -1.76 1.10 1.20 2.60 2.88 4.08 3.40 8.34
Dividend Payout % 62% 22% 8% 2% -2% 9% 17% 15% 56% 49% 59% 30%
Compounded Sales Growth
10 Years: 7%
5 Years: 11%
3 Years: 7%
TTM: 29%
Compounded Profit Growth
10 Years: 42%
5 Years: 38%
3 Years: 29%
TTM: 77%
Stock Price CAGR
10 Years: 34%
5 Years: 85%
3 Years: 17%
1 Year: 49%
Return on Equity
10 Years: 10%
5 Years: 16%
3 Years: 17%
Last Year: 19%

Balance Sheet

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 13 13 13 13 13 13 13 13 13 13 13 13
Reserves 85 82 85 97 85 91 98 109 120 146 174 227
36 39 38 8 8 4 5 7 0 6 9 9
22 19 22 25 23 28 31 35 31 30 21 29
Total Liabilities 156 154 159 143 130 136 147 164 164 195 217 278
56 52 52 22 21 22 22 26 23 24 9 94
CWIP 2 0 0 0 3 4 4 0 0 0 0 0
Investments 0 0 0 0 0 0 11 15 51 1 0 0
98 102 108 121 105 110 109 123 91 170 208 184
Total Assets 156 154 159 143 130 136 147 164 164 195 217 278

Cash Flows

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
8 4 9 -3 -2 31 11 28 7 47 35 55
-1 -0 -2 41 -3 -1 -11 -2 -26 -58 -25 -45
-4 -1 -6 -34 -1 -6 -1 -7 -18 -0 -9 -12
Net Cash Flow 2 2 1 5 -6 24 -0 19 -36 -11 2 -2

Ratios

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 115 119 106 100 73 45 49 25 26 32 19 18
Inventory Days 173 176 246 295 307 164 191 134 122 82 68 58
Days Payable 29 42 60 56 54 59 76 82 76 66 35 37
Cash Conversion Cycle 259 252 292 339 325 150 164 77 72 48 53 39
Working Capital Days 155 171 169 174 173 76 66 45 59 36 59 11
ROCE % 6% 5% 7% 3% -10% 9% 9% 18% 20% 25% 17% 23%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
68.71% 68.72% 68.72% 68.72% 68.72% 68.72% 68.48% 68.09% 68.04% 67.98% 67.82% 67.77%
0.00% 0.13% 0.11% 0.10% 0.37% 0.38% 0.53% 0.73% 1.10% 2.30% 2.10% 2.10%
0.68% 0.28% 0.77% 0.82% 0.82% 0.82% 0.82% 0.84% 0.84% 0.11% 0.00% 0.00%
30.61% 30.85% 30.40% 30.34% 30.07% 30.07% 30.16% 30.33% 30.01% 29.63% 30.10% 30.11%
No. of Shareholders 16,19414,95214,53514,08413,78216,04115,78516,28215,74815,63318,47121,085

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls